Burak Altintas, MD, an orthopedist with UTMB, who was not involved in this study, further highlighted the following limitations of the research: The limitations include retrospective design and likely residual confounding despite matching as fracture risk is influenced by many variables that are not reported [] Further, the comparison group is heterogeneous, combining another GLP-1 receptor agonist (dulaglutide) with two mechanistically different weight-loss medications
The FDA approved tirzepatide (as Mounjaro for diabetes and Zepbound for obesity) with a starting dose of 2.5 mg weekly
[DOI] [PMC free article] [PubMed] [Google Scholar] Perkins KA, Doyle T, Ciccocioppo M, Conklin C, Sayette M, & Caggiula A (2006)
Dietary restrictions, particularly around potassium, phosphate, and protein, can make eating feel stressful rather than enjoyable